Skip to main content
OpenTrials
Completed

NCT Number: NCT06619067

Efficacy Study of the Probiotic Food Supplement PROBAFLOR for Maintaining Intestinal Well-being

It is now known that intestinal health has a strong influence on the entire body. Recent research advances have demonstrated the involvement of the intestinal microbiota in the well-being of the intestine. Preventive medicine is increasingly perceived as important in medical and economic terms, particularly in the field of gastroenterology. An innovative approach to support gut health is based on the use of modulators of the intestinal microbiome or gastrointestinal barrier, such as probiotics or prebiotics. The rationale for this study is therefore based on the hypothesis that the combination of 11 probiotic strains, conveyed through the PROBAFLOR food supplement, can play a positive role in maintaining normal intestinal function, bringing benefits to the subject who takes this supplement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Scuola di Bioscienze e Medicina Veterinaria, Università di Camerino

Camerino, Macerata, 62032, Italy

About this study

This is a randomized, double-blind, placebo-controlled intervention study with a duration of 3 months of intervention + 1 month of follow-up, on biological samples. Eligible participants will be randomized and receive either the probioic or placebo supplement to consume daily for 3 months. Three check-in visits will occur, one at the screening, the second one afetr the 3-months intervention and the final one after 1 month of followup. Participants will be expected to complete a daily study diary documenting their investigational product use/adverse events and a daily bowel habits diary documenting each bowel movement. Stool samples, and questionnaires will be completed for study outcome analysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • men and women aged between 18 and 65;
  • healthy based on medical history;
  • commitment to comply with all firm procedures;
  • commitment to refrain from using any home remedies to control gastrointestinal problems, particularly if live bacteria are involved;
  • signature of informed consent.

Exclusion criteria

  • use of probiotics continuously, in the two months prior to enrollment;
  • use of antibiotics in the month before enrollment;
  • chemotherapy treatments;
  • diagnosis of respiratory, hepatic and/or renal failure;
  • Clinically significant diseases of the gastrointestinal tract (examples include, but are not limited to, celiac disease, gluten intolerance/sensitivity, inflammatory bowel disease);
  • Women who are pregnant, breastfeeding or planning to become pregnant during the study;
  • Allergy or sensitivity to the active or inactive ingredients of the investigational product.

Treatment and study plan

PROBAFLOR

Dietary Supplement

PROBAFLOR is a food supplement made up of 11 bacterial strains and inulin. The bacterial strains present are: Bifidobacterium lactis BLC1, Lactococcus lactis LL82, Lactobacillus plantarum 14D, Lactobacillus acidophilus LA1, Streptococcus thermophilus Z57, Bifidobacterium longum SP54, Lactobacillus rhamnosus SP1, Lactobacillus bulgaricus LB2, Bifidobacterium bifidum SP9,Lactobacillus salivarius SP2, Lactobacillus casei BGP93.

Placebo

Other

Placebo

Primary outcomes

  1. maintenance and/or improvement of intestinal health and health-related quality of life (through the GIQLI questionnaire)

    Time frame: Baseline, After 3 months of intervention, at follow-up (one month after the end of administration

Secondary outcomes

  1. Intestinal microbiota composition

    Time frame: Baseline, After 3 months of intervention, at follow-up (one month after the end of administration

    Metagenomic analysis on faecal samples

  2. SCFA determination

    Time frame: Baseline, After 3 months of intervention, at follow-up (one month after the end of administration

    Gas chromatographic analysis of fecal water

  3. Changes in quality of life.

    Time frame: Baseline, After 3 months of intervention, at follow-up (one month after the end of administration

    Assessed by PGWBI (The Psychological General Well-Being Index)

  4. Changes in intestinal functionality

    Time frame: Baseline, After 3 months of intervention, at follow-up (one month after the end of administration

    Assessed in accordance with the Bristol Stool Form Scale

  5. Changes on gastrointestinal symptoms

    Time frame: Baseline, After 3 months of intervention, at follow-up (one month after the end of administration

    Assessed by the GSRS (Gastrointestinal Symptom Rating Scale)

Sponsors and collaborators

Lead sponsor

Synbiotec Srl

Industry

Registry information

Official study title

Efficacy Study of the Probiotic Food Supplement PROBAFLOR for Maintaining Intestinal Well-being: Single-centre, Controlled, Randomized, Parallel Group, Double-blind Clinical Study

Acronym: PROBAFLOR

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 1, 2024
Registry last updated
Apr 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.